D. Western Therapeutics Institute (TSE:4576) Cyclically Adjusted Revenue per Share: 円0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4576 D. Western Therapeutics Institute Inc TSE:4576
45 GF Score
Price 円78.00
GF Value 円68.38
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is D. Western Therapeutics Institute Cyclically Adjusted Revenue per Share?

D. Western Therapeutics Institute TSE:4576 -1.27% 45 Cyclically Adjusted Revenue per Share is 円0.00 as of Dec. 2025. GuruFocus rates TSE:4576 with a GF Score™ of 45/100 and a GF Value™ of 円68.38 (Modestly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

D. Western Therapeutics Institute's adjusted revenue per share for the three months ended in Dec. 2025 was 円0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円0.00 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of D. Western Therapeutics Institute was 6.10% per year. The lowest was 4.90% per year. And the median was 5.50% per year.

As of today (2026-07-25), D. Western Therapeutics Institute's current stock price is 円78.00. D. Western Therapeutics Institute's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was 円0.00. D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of D. Western Therapeutics Institute was 66.26. The lowest was 5.16. And the median was 19.15.


D. Western Therapeutics Institute  (TSE:4576) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of D. Western Therapeutics Institute was 66.26. The lowest was 5.16. And the median was 19.15.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


D. Western Therapeutics Institute Cyclically Adjusted Revenue per Share Related Terms


D. Western Therapeutics Institute Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for D. Western Therapeutics Institute's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D. Western Therapeutics Institute Cyclically Adjusted Revenue per Share Chart

D. Western Therapeutics Institute Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.23 11.94 12.59 0.00 0.00

D. Western Therapeutics Institute Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.17 13.34 0.00 0.00 0.00

TSE:4576 vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


D. Western Therapeutics Institute Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio falls into.


TSE:4576
45GF Score
D. Western Therapeutics Institute Inc TSE:4576
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

D. Western Therapeutics Institute Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, D. Western Therapeutics Institute's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0/113.0000*113.0000
=0.000

Current CPI (Dec. 2025) = 113.0000.

D. Western Therapeutics Institute Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.917 98.100 1.056
201603 3.058 97.900 3.530
201606 1.045 98.100 1.204
201609 1.036 98.000 1.195
201612 1.869 98.400 2.146
201703 1.130 98.100 1.302
201706 1.909 98.500 2.190
201709 4.323 98.800 4.944
201712 2.337 99.400 2.657
201803 2.047 99.200 2.332
201806 2.479 99.200 2.824
201809 3.313 99.900 3.747
201812 3.311 99.700 3.753
201903 10.491 99.700 11.891
201906 3.333 99.800 3.774
201909 3.372 100.100 3.807
201912 4.899 100.500 5.508
202003 2.839 100.300 3.198
202006 2.922 99.900 3.305
202009 3.045 99.900 3.444
202012 3.931 99.300 4.473
202103 3.063 99.900 3.465
202106 3.812 99.500 4.329
202109 3.893 100.100 4.395
202112 3.356 100.100 3.788
202203 3.737 101.100 4.177
202206 3.408 101.800 3.783
202209 3.340 103.100 3.661
202212 4.501 104.100 4.886
202303 2.886 104.400 3.124
202306 3.058 105.200 3.285
202309 3.931 106.200 4.183
202312 3.559 106.800 3.766
202403 3.263 107.200 3.440
202406 3.578 108.200 3.737
202412 0.000 110.700 0.000
202503 2.199 111.100 2.237
202506 1.709 111.700 1.729
202509 0.000 112.000 0.000
202512 0.000 113.000 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円0.00 mean?
D. Western Therapeutics Institute (TSE:4576) has a Cyclically Adjusted Revenue per Share of 円0.00 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on D. Western Therapeutics Institute and its competitors.
Is D. Western Therapeutics Institute's Cyclically Adjusted Revenue per Share too high?
D. Western Therapeutics Institute's current Cyclically Adjusted Revenue per Share is 円0.00. Overall, D. Western Therapeutics Institute has a GF Score™ of 45/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
D. Western Therapeutics Institute's Cyclically Adjusted Revenue per Share of 円0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on D. Western Therapeutics Institute and its competitors. D. Western Therapeutics Institute's current Cyclically Adjusted Revenue per Share is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (TSE:4576) is currently considered Modestly Overvalued. The stock's GF Value™ is 円68.38, compared to a current price of 円78.00 — trading 14.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円0.00. D. Western Therapeutics Institute's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For D. Western Therapeutics Institute (TSE:4576), the current Cyclically Adjusted Revenue per Share is 円0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is D. Western Therapeutics Institute (TSE:4576) Overvalued in 2026?

Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued. The current stock price of 円78.00 is trading 14.1% above its estimated GF Value™ of 円68.38. GuruFocus considers D. Western Therapeutics Institute to be Modestly Overvalued.

Key valuation signals for TSE:4576:

  • Cyclically Adjusted Revenue per Share: 円0.00
  • GF Value™: 円68.38 vs. price of 円78.00 (14.1% above fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the TSE:4576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


D. Western Therapeutics Institute Business Description

Other Exchanges 6DW:Germany
Address 7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
45GF Score

Get the complete analysis for TSE:4576

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円78.00
Price
円68.38
GF Value